Background: Hepatitis B virus potentially accelerates graft rejection and mortality in renal transplantation population. Vaccination of graft candidates without prior immunization against HBV seems essential before transplantation but some candidates of transplantation have not received HBV vaccine at the time of receiving graft. We aimed to evaluate immunogenicity of ...

INTRODUCTION Hepatitis B vaccination starting at birth provides a safety net for infants exposed to hepatitis B virus (HBV) during delivery or in early life. Hepatitis B vaccine is recommended in the United States for infants prior to birthing facility discharge, and within the first 12h of life for infants born to hepatitis B surface antigen (HBsAg)-positive mothers. We performed a literature ...

Hepatitis B virus (HBV) infection has been a major global cause of morbidity and mortality. The recognition of the problem led to a worldwide effort to reduce transmission of HBV through routine infant vaccination. HBV infection is the most common cause of chronic liver diseases and hepatocellular carcinoma in Korea. After hepatitis B vaccine era, seroprevalence of hepatits B surface antigen is...

CONTEXT Alternative schedules more immunogenic than the standard hepatitis B vaccine regimen are needed in patients with human immunodeficiency virus 1 (HIV-1) infection. OBJECTIVE To compare the safety and immunogenicity of 4 intramuscular double-dose and 4 intradermal low-dose regimens vs the standard hepatitis B vaccine regimen. DESIGN, SETTING, AND PARTICIPANTS An open-label, multicente...

The plasma derived vaccine for hepatitis B became commercially available in 1982 but its availability was limited. The new generation of hepatitis B vaccine (recombinant rDNA yeast derived) can be produced in greater quantities at a comparable cost. Recombinant HBV vaccine given in infancy is highly immunogenic. Most infants develop antibody titre well above 10 m1U/ml, the level associated with...

Many Vaccine Information Statements are available in Spanish and other languages. See www.immunize.org/vis. 1 What is hepatitis B? Hepatitis B is a serious disease that affects the liver. It is caused by the hepatitis B virus (HBV). HBV can cause: Acute (short-term) illness. This can lead to: • loss of appetite • diarrhea and vomiting • tiredness • jaundice (yellow skin or eyes) • pain in muscl...

Chronic hepatitis B (CHB), caused by persistent virus (HBV) infection, significantly increases the risk of leading to liver diseases. Despite successful development and implementation HBV prophylactic vaccines for several decades, therapeutic vaccine, a substantially potential strategy eradicate achieve CHB cure, remains great challenge. Herein, we applied flash nanocomplexation (FNC) technolog...

 Hepatitis B virus (HBV) infection and its sequelae which include cirrhosis and hepatocellular carcinoma is a major public health problem throught the world.The WHO strategy for effective control of HBV infection is vaccination with the surface antigen of virus(HBsAg).The results obtained from a large number of studies demonstrated that the vaccine induces a protective antibody resonse (anti-HB...

UNLABELLED In persons with chronic hepatitis C virus (HCV) infections, superinfection by hepatitis A virus (HAV) or hepatitis B virus (HBV) can cause serious complications, including fulminating hepatitis or increased severity of hepatitis. Therefore, it is important to adequately protect persons with chronic HCV infections by immunization. Suboptimal response to vaccines has been reported in p...

Recently, it was suggested that maternal hepatitis B surface antigen antibodies (anti-HBs) acquired transplacentally could play a negative role in newborn infants' immune response to the hepatitis B vaccine. We compared the hepatitis B virus (HBV) vaccine response in infants born to mothers previously vaccinated against HBV (n = 91) to infants born to mothers who were not previously vaccinated ...